Login to Your Account

Clinic Roundup

Friday, January 4, 2013
• TheraVida Inc., of Mountain View, Calif., reported Phase II results showing that lead candidate Tolenix (THVD-201) produced statistically significant improvements in overactive bladder and urge urinary incontinence symptoms over placebo, and patients experienced efficacy similar in magnitude to the maximum dose of active control Detrol (2 mg tolterodine, administered twice daily).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription